By Ryan Cross
Joshua Rosenthal isn’t your typical biotech entrepreneur. The cephalopod scientist at the Marine Biological Laboratory in Woods Hole, Massachusetts, has spent most of his life studying the nervous systems of squid—along with the occasional octopus. But in April 2018, Rosenthal found himself in Boston pitching to investors at Atlas Venture an idea for a new kind of therapy, inspired by a mechanism that squid use to edit their RNA.
Caption: A model of the RNA-editing enzyme ADAR binding an antisense oligonucleotide and its target RNA. Credit: ProQR Therapeutics
Source: Watch out, CRISPR. The RNA editing race is on | Chemical & Engineering News